|Safety, activity, and immune correlates of anti–PD-1 antibody in cancer|
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
|Safety and activity of anti–PD-L1 antibody in patients with advanced cancer|
JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ...
New England Journal of Medicine 366 (26), 2455-2465, 2012
|Immune checkpoint blockade: a common denominator approach to cancer therapy|
SL Topalian, CG Drake, DM Pardoll
Cancer cell 27 (4), 450-461, 2015
|Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates|
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167, 2010
|A draft map of the human proteome|
MS Kim, SM Pinto, D Getnet, RS Nirujogi, SS Manda, R Chaerkady, ...
Nature 509 (7502), 575-581, 2014
|Inflammation in prostate carcinogenesis|
AM De Marzo, EA Platz, S Sutcliffe, J Xu, H Grönberg, CG Drake, Y Nakai, ...
Nature Reviews Cancer 7 (4), 256-269, 2007
|Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity|
SL Topalian, CG Drake, DM Pardoll
Current opinion in immunology 24 (2), 207-212, 2012
|Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeLAG-3 and PD-1 Synergistically Prevent Antitumor Immunity|
SR Woo, ME Turnis, MV Goldberg, J Bankoti, M Selby, CJ Nirschl, ...
Cancer research 72 (4), 917-927, 2012
|Role of LAG-3 in regulatory T cells|
CT Huang, CJ Workman, D Flies, X Pan, AL Marson, G Zhou, EL Hipkiss, ...
Immunity 21 (4), 503-513, 2004
|Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …|
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
|Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas|
J Zeng, AP See, J Phallen, CM Jackson, Z Belcaid, J Ruzevick, N Durham, ...
International Journal of Radiation Oncology* Biology* Physics 86 (2), 343-349, 2013
|Mechanisms of immune evasion by tumors|
CG Drake, E Jaffee, DM Pardoll
Advances in immunology 90, 51-81, 2006
|Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma|
D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ...
Science 359 (6377), 801-806, 2018
|Evidence for a Role of the PD-1: PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell CarcinomaPD-1: PD-L1 Pathway in Head and Neck Cancers|
S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ...
Cancer research 73 (6), 1733-1741, 2013
|Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017|
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
|Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity|
TJ Harris, JF Grosso, HR Yen, H Xin, M Kortylewski, E Albesiano, ...
The Journal of Immunology 179 (7), 4313-4317, 2007
|Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy|
AB Sharabi, M Lim, TL DeWeese, CG Drake
The lancet oncology 16 (13), e498-e509, 2015
|LAG 3 (CD 223) as a cancer immunotherapy target|
LP Andrews, AE Marciscano, CG Drake, DAA Vignali
Immunological reviews 276 (1), 80-96, 2017
|Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 AntibodyDurable Response and Effective Reinduction with Anti-PD-1 mAb|
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
|Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant …|
TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ...
J Clin Oncol 35 (1), 40-47, 2017